SAN FRANCISCO, July 05, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Elanco Animal Health Incorporated (NYSE:ELAN) investors who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/elan
Contact the Firm Now: ELAN@hbsslaw.com
844-916-0895
Investigation into Elanco Animal Health Incorporated (ELAN):
Elanco Animal Health is facing questions from investors regarding the accuracy of its previous statements concerning the commercial launch timelines for two key products. These products, Zenrelia, a dermatology treatment for pets, and Credelio Quattro, a broad-spectrum parasiticide, were positioned by Elanco as potential "blockbusters."
On May 8, 2024, Elanco assured investors that both products had progressed significantly through the FDA approval process. The company expressed confidence that the FDA possessed all necessary data and anticipated complete technical section and label approvals before the ...